Myungmoon Phar (017180) - Total Assets
Based on the latest financial reports, Myungmoon Phar (017180) holds total assets worth ₩272.46 Billion KRW (≈ $184.64 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore 017180 cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Myungmoon Phar - Total Assets Trend (2009–2025)
This chart illustrates how Myungmoon Phar's total assets have evolved over time, based on quarterly financial data. See Myungmoon Phar shareholders equity for net asset value and shareholders' equity analysis.
Myungmoon Phar - Asset Composition Analysis
Current Asset Composition (December 2025)
Myungmoon Phar's total assets of ₩272.46 Billion consist of 33.8% current assets and 66.2% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 2.1% |
| Accounts Receivable | ₩42.87 Billion | 15.7% |
| Inventory | ₩38.72 Billion | 14.2% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩472.33 Million | 0.2% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2009–2025)
This chart illustrates how Myungmoon Phar's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 017180 market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Myungmoon Phar's current assets represent 33.8% of total assets in 2025, an increase from 0.0% in 2009.
- Cash Position: Cash and equivalents constituted 2.1% of total assets in 2025, down from 2.9% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 7.0% in 2009.
- Asset Diversification: The largest asset category is accounts receivable at 15.7% of total assets.
Myungmoon Phar Competitors by Total Assets
Key competitors of Myungmoon Phar based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.84 Billion |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535
|
China | CN¥15.69 Billion |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
|
China | CN¥10.21 Billion |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211
|
China | CN¥6.39 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
|
China | CN¥3.23 Billion |
Myungmoon Phar - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.96 | 0.87 | 0.65 |
| Quick Ratio | 0.55 | 0.51 | 0.38 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩-4.29 Billion | ₩-12.33 Billion | ₩-43.40 Billion |
Myungmoon Phar - Advanced Valuation Insights
This section examines the relationship between Myungmoon Phar's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.59 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 5.6% |
| Total Assets | ₩272.46 Billion |
| Market Capitalization | $24.67 Million USD |
Valuation Analysis
Below Book Valuation: The market values Myungmoon Phar's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Myungmoon Phar's assets grew by 5.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Myungmoon Phar (2009–2025)
The table below shows the annual total assets of Myungmoon Phar from 2009 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩272.46 Billion ≈ $184.64 Million |
+5.61% |
| 2024-12-31 | ₩257.99 Billion ≈ $174.83 Million |
+9.06% |
| 2023-12-31 | ₩236.55 Billion ≈ $160.31 Million |
+2.65% |
| 2022-12-31 | ₩230.45 Billion ≈ $156.17 Million |
+3.49% |
| 2021-12-31 | ₩222.68 Billion ≈ $150.90 Million |
-8.37% |
| 2020-12-31 | ₩243.03 Billion ≈ $164.69 Million |
-8.10% |
| 2019-12-31 | ₩264.44 Billion ≈ $179.21 Million |
+8.79% |
| 2018-12-31 | ₩243.07 Billion ≈ $164.72 Million |
+3.40% |
| 2017-12-31 | ₩235.08 Billion ≈ $159.31 Million |
+6.33% |
| 2016-12-31 | ₩221.08 Billion ≈ $149.82 Million |
+10.86% |
| 2015-12-31 | ₩199.42 Billion ≈ $135.14 Million |
+4.59% |
| 2014-12-31 | ₩190.66 Billion ≈ $129.21 Million |
-0.91% |
| 2013-12-31 | ₩192.41 Billion ≈ $130.39 Million |
+2.16% |
| 2012-12-31 | ₩188.34 Billion ≈ $127.63 Million |
-7.00% |
| 2011-12-31 | ₩202.50 Billion ≈ $137.23 Million |
+23.36% |
| 2010-12-31 | ₩164.15 Billion ≈ $111.24 Million |
+6.70% |
| 2009-12-31 | ₩153.85 Billion ≈ $104.26 Million |
-- |
About Myungmoon Phar
MYUNGMOON Pharm co.,Ltd engages in the research, development, production, distribution, and sale of pharmaceuticals in South Korea and internationally. It offers prescription drugs, including anti osteoarthritis, anti-inflammatory analgesics, antiphlogistic enzymes, muscle relaxant, anti rheumarthritis, antibiotics and antifungal, respiratory agents, GI therapeutics, circulation agents, anti-hype… Read more